Streetwise Reports Examines How 'Exciting' Collaborations Possible for Biotech's 'Flexible' Platform Print E-mail
By GLOBE NEWSWIRE   
Thursday, 21 December 2017 02:00

SAN FRANCISCO, Dec. 21, 2017 (GLOBE NEWSWIRE)

SAN FRANCISCO, Dec. 21, 2017 (GLOBE NEWSWIRE) -- Zacks Small-Cap Research's John Vandermosten discussed the potential for this immunotherapy firm's RNAi compounds in oncology.

Included in this article is: RXi Pharmaceuticals Corp. (NASDAQ:RXII)

In a Dec. 7 Zacks Small-Cap article, John Vandermosten explained how RXi Pharmaceuticals Corp.'s self-delivering RNA interference (sd-rxRNA) technology may be used in conjunction with adoptive cell transfer (ACT) cancer therapies to "enhance their effectiveness and durability."

These ACT processes include endogenous T-cell therapy, T-cell receptor-transduced T cells and, currently most researched, tumor infiltrating lymphocyte (TIL) therapy and chimeric antigen receptor T-cell (CAR-T) therapy. The most common disease targets for TIL therapy are melanoma and solid cancers whereas for CAR-T therapy they are leukemia, lymphoma and other blood cancers.

Vandermosten noted that "ACT is especially conducive to combination therapy with interference RNA (RNAi) as it can augment ACT's efficacy, impact expression of immune cell proteins and maintain immune cells in a stem-like state, which enhances their propagation and

longevity."

Continue reading this article: 'Exciting' Collaborations Possible for Biotech's 'Flexible' Platform 

About Streetwise Reports – The Life Sciences Report

Investors rely on The Life Sciences Report to share investment ideas for the biotech, pharmaceutical, medical device, and diagnostics industries. The information provided above is for informational purposes only and

Error. Page cannot be displayed. Please contact your service provider for more details. (16)

is not a recommendation to buy or sell any security.

DISCLOSURES:

The following company mentioned in this article is a billboard sponsor of Streetwise Reports: RXi Pharmaceuticals Corp. Streetwise Reports does not accept stock in exchange for its services. Click here for important disclosures about sponsor fees. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security.
3) Comments and

opinions expressed are those of the specific experts and not of Streetwise Reports or its officers. 

Please see the end of the article for the complete disclosures: : 'Exciting' Collaborations Possible for Biotech's 'Flexible' Platform 

Contact Information: Carrie Beal Amaro- Publisher (cbealamaro@streetwisereports.com)

Primary Logo




BiomedReports is not paid or compensated by newswires to disseminate or report news and developments about publicly traded companies, but may from time to time receive compensation for advertising, data, analytics and investor relation services from various entities and firms. Full disclosures should be read in the 'About Us Section'.

Add this page to your favorite Social Bookmarking websites
Digg! Reddit! Del.icio.us! Mixx! Google! Live! Facebook! Technorati! StumbleUpon! MySpace! Yahoo!
 

Newsletter

BMR:1